ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Identification and Validation of RPL7 and RCCD1 as Potential Biomarkers Associated with Immune Infiltration in Patients with Thin Endometrium.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Thin endometriumQuery (TE) significantly contributes to poor embryo implantation and female infertility, yet its pathogenesis remains unclear, limiting effective treatment options. To identify potential TE-associated genes and explore underlying mechanisms for clinical therapy, we conducted RNA sequencing on 18 TE and 18 normal endometrium samples, followed by bioinformatics analysis. Total RNA was extracted from samples, reverse-transcribed into cDNA, and sequenced on the HiSeq 2500 platform, followed by differential expression analysis and functional enrichment of differentially expressed genes (DEGs). Functional enrichment and LASSO analysis identified key biomarkers, which were subsequently validated at both mRNA and protein levels. Immune infiltration patterns and correlations with immune cells were also examined. Consequently, ribosomal protein L7 (RPL7) and RCC1 domain-containing 1 (RCCD1) were identified as potential biomarkers, showing overexpression in TE and association with abnormal immune regulation. These findings suggest that RPL7 and RCCD1 may serve as specific biomarkers for TE, providing insights that could aid in developing targeted therapeutics to improve clinical outcomes.
Indexed as
Identifiers
40457017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.